Avidity Biosciences (RNAM) Stock Overview
A biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
RNAM Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Avidity Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$72.82 |
| 52 Week High | US$73.06 |
| 52 Week Low | US$21.51 |
| Beta | 0.93 |
| 1 Month Change | 0.50% |
| 3 Month Change | 1.56% |
| 1 Year Change | 137.66% |
| 3 Year Change | 195.30% |
| 5 Year Change | 217.16% |
| Change since IPO | 155.51% |
Recent News & Updates
Recent updates
Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota
Sep 11Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Apr 23
Avidity Biosciences: Looks Tempting, But Wait For Interim Phase 3 Data
Feb 24Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term
Oct 02Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders
Aug 16Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade
Jun 14Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline
May 19Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
Feb 29Avidity slips 20% as FDA places lead asset on partial clinical hold
Sep 27Avidity stock rises amid Chardan starting coverage with Buy
Jul 20Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides
Jul 12Shareholder Returns
| RNAM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.05% | -0.4% | 0.6% |
| 1Y | 137.7% | 29.3% | 18.4% |
Return vs Industry: RNAM exceeded the US Biotechs industry which returned 29.3% over the past year.
Return vs Market: RNAM exceeded the US Market which returned 18.4% over the past year.
Price Volatility
| RNAM volatility | |
|---|---|
| RNAM Average Weekly Movement | 0.4% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RNAM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RNAM's weekly volatility has decreased from 10% to 0% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 511 | Sarah Boyce | www.aviditybiosciences.com |
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company’s pipeline has three programs in clinical development, such as Delpacibart zotadirsen which is in Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy; Delpacibart etedesiran which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; and Delpacibart braxlosiran that is in Phase 1/2 development stage for the treatment of facioscapulohumeral muscular dystrophy.
Avidity Biosciences, Inc. Fundamentals Summary
| RNAM fundamental statistics | |
|---|---|
| Market cap | US$11.30b |
| Earnings (TTM) | -US$684.63m |
| Revenue (TTM) | US$18.76m |
Is RNAM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RNAM income statement (TTM) | |
|---|---|
| Revenue | US$18.76m |
| Cost of Revenue | US$559.16m |
| Gross Profit | -US$540.40m |
| Other Expenses | US$144.23m |
| Earnings | -US$684.63m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.41 |
| Gross Margin | -2,881.39% |
| Net Profit Margin | -3,650.39% |
| Debt/Equity Ratio | 0% |
How did RNAM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/27 18:20 |
| End of Day Share Price | 2026/02/26 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Avidity Biosciences, Inc. is covered by 18 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Pickering | Bernstein |
| Tazeen Ahmad | BofA Global Research |
| Eric Schmidt | Cantor Fitzgerald & Co. |